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Gut Motility disorders comprise a heterogeneous group of disorders that result from disruption of the 
functional integrity of the intrinsic neuromusculature of the gastrointestinal (GI) tract. This intrinsic 
neuromusculature includes the smooth muscle layers, the intrinsic nervous system of the GI tract (enteric 
nervous system or ENS) and the interstitial cells of Cajal.  The contribution of each of these components to 
function can be compromised by alterations in structure (ranging from absence to derangement in numbers 
and/or anatomy) or of function (complete or partial failure in physiological function). This pathology can be 
primary or secondary to a number of insults e.g. infections, inflammation, toxins etc. In children disorders 
may be congenital being present from birth or acquired later in life. Finally involvement of the enteric 
neuromusculature can be patchy/segmental or affect the gastrointestinal tract diffusely. 
Neuro-gastroenterology is the study of the interface of all aspects of the gastrointestinal tract or 
digestive system with the different branches of the body’s nervous system including the enteric, central and 
autonomic nervous systems. The combined terms ‘Neurogastroenterology and motility’ are designed to 
encompass the study of all the components of the enteric neuromuscualture and their modulating influences 
and represents one of the fastest growing areas in gastroenterology clinical practice and research.  This 
chapter aims to address some of the most common neurogastroenterology and motility conditions seen in 
clinical practice ranging from those with defined pathology to those which fall under the umbrella of 
functional gastrointestinal disorders. The latter comprise some of the commonest but challenging disorders 
and the term ‘functional’ reflects the fact that in the majority of such conditions no organic cause can be 
found. It should also be noted that at the present time many functional disorders e.g. abdominal pain-related 
functional GI disorders, represent symptom complexes that can further be subdivided into more discrete 
entities e.g. irritable bowel syndrome, functional abdominal pain etc depending on the nature, location and 
associations of the symptoms. Clinicians will often rely on the presence or absence of ‘red flags’ e.g. 
associated weight loss, severe or significant symptoms etc to decide whether patients are likely to have 
organic or functional disorders. Exhaustive investigations in the latter are likely to prove fruitless, expensive 
and perpetuate ‘illness behaviours’ in the patients.   
 
Abdominal pain-related functional gastrointestinal disorders 
 
Introduction 
Abdominal pain-related functional gastrointestinal disorders (FGID) constitute a spectrum of conditions 
characterised by the presence of recurrent abdominal pain in the absence of any defined pathology 1. In the 
past these disorders fell under the single term ‘Recurrent abdominal pain’ (RAP) but have since been re-
categorised under an international initiative (Rome Foundation) to improve the diagnosis and classification 
of such conditions. The Rome III criteria 2,3 are currently being utilised (summarised in Tables 1-5). 
RAP is frequently encountered as a presenting complaint in pediatrics 4,5. In the majority of patients no 
organic disease is identified 6. Despite its benign nature the persistence of symptoms can result in significant 
stress to children and their families as well as clinicians concerned at the possibility of missing an underlying 
pathology. With the implementation of the Rome III criteria, abdominal pain-related FGID, have been 
framed as a positive diagnosis rather than one of exclusion 3, which will hopefully facilitate the reduction of 
unnecessary diagnostic procedures and expedite the initiation of appropriate treatment 7. 
 
Epidemiology 
The prevalence of childhood abdominal pain-related FGID in western countries has been estimated to be 
between 0.3 to 19% 8. Various definitions and diagnostic criteria used for such disorders prior to the 
development of the ROME III criteria are likely to have accounted for the wide range of the reported 
prevalence.  
 
Pathophysiology 
The pathophysiological model for abdominal pain-related FGIDs is undoubtedly multifactorial  9. It has been 
proposed that various mechanisms such as genetics, early life events, environmental, gastrointestinal and 
psychosocial factors act together in a complex interplay ultimately resulting in an alteration to the gut-brain 
axis 10,11,12,13,14,15,16. Afferent signals from the gastrointestinal tract transmitted via the pain pathways are 
subsequently amplified and the patient’s perception of painful stimuli is in turn enhanced 17. These 
phenomena have been defined as visceral hypersensitivity and central hypervigilance respectively14.  
 
Clinical presentation 
According to Rome III criteria abdominal pain-related FGIDs can be classified into the following five 
categories: Functional Abdominal Pain (FAP), FAP syndrome, functional dyspepsia, abdominal migraine 
and irritable bowel syndrome (IBS). 
 
Tables 1-5. Rome III diagnostic criteria for abdominal pain-related FGID (adapted from Rasquin A. et al.3). 
Table 1. Diagnostic criteria for FAP in children 
All of the following criteria must be present at least once a week for a period of ≥2 months prior to the 
diagnosis: 
1. Abdominal pain (intermittent or continuous) 
2. Criteria insufficient for the diagnosis of other abdominal pain-related FGID 
3. Absence of evidence of possible organic disease that could account for patient’s symptomatology 
 
Table 2. Diagnostic criteria for FAP Syndrome in children 
FAP must be present at least 25% of the time plus ≥1 of the following: 
1. Some loss of functioning on a daily basis 
2. Presence of somatic symptoms (e.g. headache, sleeping difficulties, limb pain) 
The above criteria must be present at least once a week for a period of ≥2 months prior to the diagnosis. 
 
 
Table 3. Diagnostic criteria for functional dyspepsia in children 
All of the following criteria must be present at least once a week for a period of ≥2 months prior to 
diagnosis: 
1. Presence of pain (persistent or recurrent) or discomfort localised in the upper abdomen (above the level of 
umbilicus) 
2. Criteria insufficient for the diagnosis of IBS 
3. Absence of evidence of possible organic disease that could account for patient’s symptomatology 
 
Table 4. Diagnostic criteria for abdominal migraine in children 
All of the following criteria must be present at least once a week for a period of ≥2 months prior to 
diagnosis: 
1. Paroxysms of intense and acute periumbilical pain (duration ≥1 hour) 
2. Intervals of usual health (duration: weeks to months) between the episodes of pain 
3.The pain affects child’s normal activities 
4.The pain is associated with ≥2 of the following: 
a. Anorexia 
b.Nausea 
c. Vomiting 
d. Headache 
e. Photophobia 
f. Pallor 
4. Absence of evidence of possible organic disease that could account for patient’s symptomatology 
 
Table 5. Diagnostic criteria for IBS in children 
1. Abdominal discomfort or pain associated with ≥2 of the following at least 25% of the time: 
a. Improvement with defecation 
b. Onset of pain associated with a change in the frequency of bowel motions 
c. Onset of pain associated with a change in the consistency (form) of stools 
2. Absence of evidence of possible organic disease that could account for patient’s symptomatology 
The above criteria must be present at least once a week for a period of ≥2 months prior to the diagnosis. 
 
During history taking, physical examination and interpretation of first-line blood tests, there are certain 
features that may suggest the presence of an underlying organic pathology. Physicians need to be aware of 
these “red-flag” signs/symptoms, which are summarised in Table 6 1. 
 
Table 6. ‘Red flag’ or alarm features that may suggest the presence of an underlying organic pathology for 
recurrent abdominal pain in children 
From history 
Onset of symptoms <5 years of age 
Presence of constitutional symptoms (eg fever, weight loss) 
Presence of nocturnal symptoms (eg pain that awakens the child, diarrhea) 
Gastrointestinal bleeding 
Vomiting 
Dysphagia 
Persistent right upper or lower abdominal quadrant pain 
Presence of referred pain (back, shoulders, extremities) 
Dysuric symptoms 
Family history of inflammatory bowel disease, celiac or peptic ulcer disease 
From physical examination 
Faltering growth, delayed puberty 
Hepato-splenomegaly 
Jaundice 
Signs of perianal disease (tags, fissures, fistulas) 
From first-line blood test 
Anaemia, neutropenia or thrombocytopenia 
Hypoalbuminemia 
Elevated inflammatory markers (white blood cell count, erythrocyte sedimentation rate, C-reactive protein) 
 
The identification of alarm features should guide the diagnostic procedure towards excluding an organic 
disease. Amongst the myriad of pathologies that could potentially present with abdominal pain Table 7. 
below lists those most frequently encountered in pediatrics. 
Table 7. Potential organic disorders as differential diagnoses of recurrent abdominal pain 
Gastrointestinal system 
Gastroesophageal reflux 
Peptic ulcer disease 
Coeliac disease 
Eosinophilic gastrointestinal disease 
Food allergy 
Inflammatory bowel disease 
Chronic constipation 
Malrotation 
Hernias 
Intussusception 
Tumors (eg lymphoma) 
 
Pancreatic and hepatobiliary 
Cholelithiasis 
Cholecystitis 
Chronic hepatitis 
Chronic pancreatitis 
 
Respiratory system 
Pneumonia 
 
Genitourinary system 
Nephrolithiasis 
Pyelonephritis/Cystitis 
Ureteropelvic junction obstruction 
Hematocolpos 
 
Musculoskeletal system 
Trauma 
Tumors 
 
Other systems 
Sickle cell disease 
Leukemia 
Diabetes mellitus 
Porphyria 
Familial mediterranean fever 
Lead poisoning 
 
 
Diagnostic investigations 
Laboratory tests, imaging studies and endoscopic procedures should be performed wisely and guided by the 
information obtained from the history and physical examination. Although there is lack of evidence to 
evaluate the usefulness of blood tests as a discriminatory tool between functional and organic disease, a 
limited number of first line tests may be warranted. It has been proposed that these should include a full 
blood count with differential, erythrocyte sedimentation rate, C-reactive protein, coeliac serology, urinalysis, 
urine culture, and faecal examination for ova and parasites 18,19. Extensive diagnostic investigations should be 
avoided as they are usually not clinically indicated, are of significant financial cost and ultimately impair the 
physician-patient relationship as they increase patient’s uncertainty regarding the diagnosis and the overall 
treatment plan 1. 
 
Treatment 
The management plan of the childhood FAP should be based on the biopsychosocial model for FGID and 
needs to incorporate a multidisciplinary approach specifically developed to each child’s symptomatology and 
identifiable triggers 17.  
Dietary interventions (such as food elimination diets) and use of probiotics have shown favourable results in 
certain groups of patients with FAP, however more data are needed in order to fully evaluate their 
therapeutic efficacy 20,21.  
Psychosocial interventions (eg parental education, family therapy, relaxation, distraction, hypnotherapy, 
biofeedback) are also very effective in reducing the severity and maintenance of somatic symptoms in 
children with abdominal pian-related FGID 22. Indeed it has been shown that hypnotherapy in particular is a 
highly beneficial therapeutic modality even when compared to conventional medical care resulting in long-
term remission in children with either FAP or IBS 23,24. More work needs to address the modalities and 
resources needed to deliver hypnotherapy in the broader clinical arena. 
 
Certain groups of drugs such as antidepressants (eg tricyclic antidepressants, serotonin reuptake inhibitors), 
antispasmodics (eg peppermint oil, hyoscyamine), cyproheptadine and prokinetics (eg domperidone, 
erythromycin) have been reported to be successful in the treatment of childhood FAP and are used widely, 
albeit variably 25,26,27,28,29. There is, however, a clear lack of well-controlled trials to precisely support the 
efficacy long-term of the aforementioned medications in the pediatric population. Thus the benefit of their 
use in clinical practice is yet to be elucidated 30. With regard to complementary and alternative medicine 
(herbal preparations, acupuncture) there are currently no sufficient data to support their potential therapeutic 
role in childhood FAP 18,31. 
Overall, robust randomised placebo-controlled trials are needed to assess these agents especially given 
reports of substantial placebo effects of up to 50% 32. 
 
Prognosis 
Long-term follow-up of children with RAP reveals that 35-50% of them will eventually progress to complete 
resolution of their symptoms, whereas at least 25% will continue to experience abdominal pain in adulthood. 
Amongst children with RAP those who had been given a clear and simple explanation of their condition 
along with the physician’s reassurance were less likely to express extra-abdominal complaints or relapse 
later in life 33,34,35. Male gender, onset of symptoms at an age younger than 6 years, duration of symptoms >6 
months, low educational and socioeconomic status, presence of a so-called ‘painful family’ and an increased 
number of surgical procedures (eg tonsillectomy, appendectomy) have been established as poor prognostic 
indicators for the long-term outcome of children with RAP 33,35. 
 
Conclusions 
Abdominal pain-related FGIDs may result in a significant impairment of the well being of children and their 
families as well. The role of the physician is crucial in advising the family to adopt appropriate parenting 
styles, which create a supportive and loving environment that subsequently reduces the anxiety caused in 
children by minor injuries/illnesses and other stressful situations that they may encounter.  
The diagnostic approach and therapeutic management of a child presenting with RAP may be challenging. A 
detailed history combined with a thorough clinical examination as suggested by the Rome III criteria remains 
the cornerstone for diagnosis. Baseline laboratory investigations may aid the establishment of a positive 
diagnosis of FGID, thereby leading to prompt appropriate management and better long-term outcomes. 
 
 
 
 
 
 
 
 
Functional Constipation 
 
Introduction 
     Chronic constipation is a common problem in children with a reported prevalence of between 0.7% and 
29.6% (median 12%) 36. Most often it is defined as a delay or difficulty in defecation present for at least 2 
weeks sufficient to cause significant distress to the patient 37. A normal pattern of stool evacuation is 
commonly thought to be a sign of health in children of all ages. Especially during the first months of life, 
parents pay close attention to the frequency and the characteristics of their babies’ defecation. Any deviation 
from what they thought to be normal may trigger a call to the nurse or a visit to the pediatrician. Thus, it is 
not surprising that approximately 3% of general pediatric outpatient visits and 25% of pediatric 
gastroenterology consultations are related to a perceived defecation disorder 38. Chronic constipation is an 
important source of anxiety for parents who often worry that a serious disease is causing the symptom, 
accepting that beyond the neonatal period, the most common cause of constipation in children is functional 
with only a small minority of children thought to have an organic cause.   
 
 
Pathophysiology 
Functional constipation is defined as constipation without objective evidence of a pathological condition and 
is thought to result from painful bowel movements with consequent voluntary withholding of feces by a 
child who wants to avoid unpleasant defecation. Several events can lead to painful defecation such as toilet 
training, changes in routine or diet, stressful events, intercurrent illness, deliberate avoidance or 
unavailability or of toilets e.g. at school, or the child’s postponing defecation because he or she is too busy. 
Withholding feces can lead to protracted fecal stasis in the colon with resorption of fluids leading to both a 
change in stool consistency and an increase in their overall size. The passage of large, hard stools that 
painfully stretch the anus may frighten the child and result in a fearful determination to avoid all defecation.  
Such children respond to the urge to defecate by contracting their anal sphincter and gluteal muscles, 
attempting to withhold stool 39,40. Eventually, the rectum habituates to the stimulus of the enlarging fecal 
mass, and the urge to defecate slackens. After a while, such retentive behavior becomes an automatic 
reaction. As the rectal wall stretches, fecal soiling may occur, angering the parents and frightening the child 
41. After several days without a bowel movement, irritability, abdominal distension, cramps, and decreased 
oral intake may appear. 
 
Diagnosis 
Currently, the most widely accepted criteria to diagnose childhood functional constipation are the Rome III 
criteria (Table 1) 2,3. There are 2 sets of criteria based on the age of the patient (i.e. below and above the age 
of 4 years) and the diagnosis is based on careful clinical history and examination. The history should include 
both a personal (e.g. age at first passage of meconium and onset of symptoms, acquisition of developmental 
milestones and growth parameters, associated symptoms including bilious vomiting or rectal bleeding etc) as 
well as family history (e.g. gastrointestinal disease, allergy, other non-gastrointestinal disorders etc). 
Examination should focus on general well-being, growth parameters, the abdomen for organomegaly, 
distention and masses, inspection of the anus, as well as examination of the lumbosacral spine and 
neurology. Table 2 lists a number of ‘red flags’ that should alert the clinician to the possibility of organic 
disease underlying the constipation. The presence of one or more of these should raise the suspicion for 
organic cause of constipation and need for further workup. It should be noted that this list is not exhaustive. 
 
 
Table 1. Rome III criteria for children aged below and above 4 years (adapted from references2,3) 
Rome III diagnostic criteria for functional constipation in children up to 4 years of age * 
Two or fewer defecations per week 
At least one episode/week of incontinence after the acquisition of toileting skills 
History of excessive stool retention 
History of painful or hard bowel movements 
Presence of a large fecal mass in the rectum 
History of large diameter stools which may obstruct the toilet 
* must include one month of at least 2 of the following 
 
  
Rome III diagnostic criteria for functional constipation in children older than 4 years of age * 
1. Must include two or more of the following: 
- Straining during at least 25% of defecations 
- Lumpy or hard stools in at least 25% of defecations 
- Sensation of incomplete evacuation for at least 25% of defecations 
- Sensation of anorectal obstruction/blockage for at least 25% of defecations 
- Manual maneuvers to facilitate at least 25% of defecations (e.g., digital evacuation, support of the 
pelvic floor) 
- Fewer than three defecations per week 
2. Loose stools are rarely present without the use of laxatives 
3. Insufficient criteria for irritable bowel syndrome 
*criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis 
 
Table 2. Red flags 
Main red flags for organic constipation 
Delayed passage of meconium after birth (> 48 hours) 
Early onset (first months of life) 
Family history of Hirschsprung disease  
Growth failure 
Abnormal examination of lumbosacral spine (sacral dimple, patch of hair, gluteal cleft deviation) 
Abnormal neurological examination of anal reflexes and/or lower limbs 
Abnormal anus (position, scars, fistulae) 
Other significant signs or symptoms (blood in stools in the absence of visible anal fissures, massive 
abdominal distention, bilious vomiting, fever) 
Unusual history and examination findings (consistent empty rectal ampulla on rectal examination, absence 
of withholding or fecal incontinence, extreme anal phobia) 
 
Investigations 
     A thorough history and physical examination is usually sufficient to allow the practitioner to establish 
whether the child requires further investigation or has functional constipation. The presence of ‘red flags 
should alert the clinician to the possible need for further testing to exclude organic pathology. Metabolic 
tests, such as serum calcium level and thyroid function tests, X-ray abdomen, barium enema, anorectal 
manometry, suction rectal biopsy, colonic manometry, magnetic resonance imaging of the lumbosacral 
spine, and psychological evaluation may be helpful in order to rule out a possible organic cause of 
constipation. These should be performed in liaison with a paediatric gastroenterologist. 
 
Treatment 
     The general approach to the child with functional constipation includes four sequential phases: parental 
education, elimination of the fecal mass if present, maintenance therapy to prevent fecal re-accumulation, 
and close follow-up for a sufficient time-period to adjust medications as necessary 1,42. The education of the 
family should include the demystification of constipation and an explanation of its pathogenesis.  Moreover, 
parents are encouraged to maintain a consistent, positive, and supportive attitude in all aspects of treatment. 
If a fecal mass is present, disimpaction must be carried out before initiation of maintenance therapy and may 
be accomplished by either the oral or rectal route.  The oral approach is less invasive and gives a sense of 
power to the child, but adherence to the treatment regimen may be a problem, particularly given the 
increased fecal incontinence seen with the use of polyethylene glycol 43. The rectal approach is faster but is 
invasive and may become more challenging with repeated use. Oral (with polyethylene glycol) and rectal 
disimpaction have been shown to equally effective 43 and the choice of treatment is best determined after 
discussing the options with the family and child. Disimpaction with oral medication has been successfully 
reported with high doses of mineral oil, polyethylene glycol electrolyte solutions, or both 44,45,46,47,48. Rectal 
disimpaction may be performed with phosphate, saline, or mineral oil enemas alone or in combination49,50.  
Once the impaction has been removed, the treatment focuses on maintenance therapy to prevent recurrence.  
This treatment consists of dietary interventions, behavioral modification, and laxatives to assure that bowel 
movements occur at normal intervals with good evacuation.  Multiple laxatives have been routinely used in 
the treatment of childhood constipation with a number of new agents currently being trialed, mostly in adults 
51. At the present time published evidence suggests that polyethylene glycol 3350 should be the laxative of 
first choice in pediatrics for functional constipation 42,51,52,53,54. Enemas do not appear to carry any added 
benefit and should not be used routinely for maintenance therapy 55. Increased intake of fluids and the use of 
absorbable and non-absorbable carbohydrate, and more recently pro- and pre-biotics, are commonly advised 
as methods to soften stools and improve defaecation frequency.  Current evidence, however, does not 
support their routine use as supplementation over and above a normal intake, for the treatment of functional 
constipation 51. Finally, an important component of treatment includes behavior modification and regular 
toilet habits, including unhurried time on the toilet after meals, although on their own these are unlikely to 
result in long-term sustained benefit 56. Surgical interventions have little role in the management of 
functional constipation although there have been reports of success with the use of antegrade continence 
enemas in children with an intractable course 57. Data on transcutaneous and sacral nerve stimulation is 
emerging and does not yet have a routine place in treatment 58.  
 
Prognosis and long-term outcomes  
A systematic review of functional constipation follow-up studies suggested that almost two-thirds of children 
are found to be free from symptoms after 6 to 12 months of laxative treatment. Recovery rates appear to be 
better with early and sustained intervention with laxative treatment. Outcomes showed no relation with 
defecation frequency or positive family history and studies have been unable to identify a group of children 
at most risk of poor prognosis 59,60,61. Long-term treatment and follow-up, with early therapeutic 
interventions of relapses remains an integral part of successful management of functional constipation 42,62. 
Chronic Intestinal Pseudo-obstruction 
 
Introduction 
Chronic Intestinal Pseudo-Obstruction (CIPO) comprises a rare and heterogeneous group of conditions that 
variably affect one or more of the intrinsic gut components that govern intestinal motility namely the enteric 
nerves, muscles and interstitial cells of Cajal (ICCs) or affect their modulating influences. This impairs the 
ability of the intestine to propel its contents and CIPO is defined and characterised by repetitive episodes or 
continuous symptoms and signs of intestinal obstruction in the absence of a fixed, lumen-occluding lesion, 
which may be associated with radiological evidence of dilated bowel with fluid levels 62,63. Although the true 
incidence and prevalence of CIPO conditions across the world are unclear, scanty epidemiological data 
suggest they are rare with an estimated incidence of approximately 1 in 40,000 live births 64.  
 
Pathophysiology 
Conditions can be classified by whether they primarily affect intestinal smooth muscle (myopathies), nerves 
(neuropathies) or ICCs (mesenchymopathies) and can further be subdivided into primary or secondary, 
congenital or acquired, inheritance and what area of the gut they primarily involve 63. CIPO in children most 
commonly occurs sporadically, is congenital and primary, and affects the intestine diffusely. At the present 
time, although mesenchymopathies have been implicated in a few reports, the majority of conditions are 
classified as neuropathies and myopathies 65,66,67,68,69. For the majority this is adequately achieved through 
appropriate, often specialised, functional assessment and histopathology. 
CIPO may also occur in association with other conditions affecting other systems of the body. Most 
commonly affected, more so in myopathies than neuropathies, is the urinary tract 67. Specific conditions 
include hollow visceral myopathy and Megacystis—microcolon intestinal hypoperistalsis syndrome 70. Other 
associations include connective tissue disorders, muscular dystrophies and autonomic disorders. CIPO may 
also occur secondary to intestinal surgery and a range of toxins, endocrine and metabolic defects. More 
recently, neuropathic viruses have been implicated in adult patients with CIPO 71. 
The genetics of CIPO is poorly characterised. In those that have been reported there appears to be a 
heterogeneous pattern of inheritance consisting of autosomal recessive (AR), autosomal dominant (AD) and 
X-linked (XL) 72. Genes implicated include those for the transcription factor Sox10 (AD), filamin A (XL), 
and the L1 cell adhesion molecule (XL). CIPO is also seen in the context of mitochondrial disorders caused 
by mutations in the thymidine phosphorylase (Mitochondrial Neuro-Gastro-Intestinal Encephalomyopathy 
(MNGIE) syndrome) or in the polymerase-gamma genes (MNGIE without leukoencephalopathy) 73.  
 
Clinical Presentation 
Patients with CIPO typically present with recurrent or continuous sub-occlusive episodes, which resemble 
intestinal mechanical obstruction. Patients with congenital CIPO typically present early in life with the 
majority being diagnosed within the first few weeks and months of life. Some of these will present in utero 
with a dilated urinary tract or abdominal distention. Approximately a third of children with congenital CIPO 
have intestinal malrotation 67. 
Symptoms vary according to age at presentation and the part of the gastrointestinal tract primarily 
affected. They commonly include vomiting (which is often bilious) and abdominal distension. Other 
symptoms variably include abdominal pain, anorexia, poor weight gain, constipation and diarrhoea.  Other 
symptoms may result from involvement of other organ systems e.g. urinary tract (megacystis with increased 
bladder compliance and capacity and poor detrusor contractility, ureterohydronephrosis, recurrent UTIs). A 
most severe condition involving both the intestine and urinary system is megacystis-microcolon intestinal 
hypoperistalsis syndrome 71. Symptoms may also be secondary to complications e.g. diarrhoea from bacterial 
overgrowth. Exacerbation of symptoms may be precipitated by various causes including intercurrent 
infections and stress. 
The clinical course is generally characterised by relapses and remissions leading, in a small 
proportion, to gradual decompensation of intestinal function and ultimately to intestinal failure. This is more 
likely in severe cases, and those presenting late and/or that have been inadequately treated. 
 
Diagnosis 
Although this may be suspected from the clinical history (including family history) and course of the disease, 
it is often difficult because of the varied clinical presentation and limitations in the availability of specific or 
specialised diagnostic testing. Plain abdominal radiographs classically show a dilated gastrointestinal tract, 
which may contain air-fluid levels (Figure 1). Contrast studies often show marked delays in intestinal transit 
and may reveal other abnormalities such as malrotation and microcolon. Water-soluble contrast should be 
used instead of barium to prevent insipissation of contrast. Unfortunately, children with CIPO often undergo 
repeated and complex gastrointestinal surgery (including resection of dilated loops of bowel), which is 
neither diagnostic nor curative, before a diagnosis is finally made. A diagnosis of pseudo-obstruction should 
be suspected if there are symptoms of a generalised dysmotility (vomiting, abdominal distension and 
constipation) especially when they occur recurrently or chronically with no symptom free intervals.  
Associated urinary symptoms and autonomic nervous system dysfunction may also be suggestive. Review of 
previous radiological studies and histopathology may be helpful.  
A more definitive diagnosis relies on following a number of specific steps:- 
1. Exclusion of any mechanical obstructive lesion of the gastro-intestinal tract (X-rays, contrast studies 
or by previous exploratory surgery). 
2. Confirmation of abnormal motility (functional motility testing e.g. oesophageal manometry, 
electrogastrography, gastric emptying studies, bowel transit studies, small and large bowel 
manometry). An abnormal small intestinal (antroduodenal) manometry study, with disruption of the 
phasic fasting motor activity, is classically associated with CIPO (Figure 2) 73 
3. Search for an underlying cause for the pseudo-obstruction, including potentially treatable ones.  This 
may include, for example, assessment of haematological parameters, blood chemistry, metabolic 
screening, toxicology, infections, connective tissue diseases etc. Histopathological assessment is 
often valuable in the diagnosis and classification of CIPO. Limitations and variability in expertise 
and availability of specialised histopathological tools are a significant problem. International 
initiatives are underway to improve the diagnostic yield and ultimate classification of CIPO 
disorders 74,75,76.  
Paediatric condition falcification has been recognised in children presenting with potential CIPO 77. Small 
intestinal manometry in such children is often normal in direct contrast to those suffering from CIPO. 
 
Treatment 
Unfortunately the management of CIPO has seen little real progress and essentially remains supportive to:  
1. maintain nutrition  
2. preserve growth and development 
3. limit symptoms and improve quality of life  
4. limit complications such as bacterial overgrowth and life-threatening sepsis.   
 Nutrition aims to maintain maximally tolerated enteral feeds with use of parenteral nutrition (PN) as 
required.  In our experience although most of the CIPO children had ileostomy formation to decompress the 
bowel and reduce afterload, three quarters of the myopathic CIPO remained dependent on PN as a main 
source of nutrition and fluid long-term as opposed to just over a third of the neuropathic CIPO patients. (N. 
Thapar, unpublished). Maintaining patients on maximally tolerated enteral nutrition preserves  intestinal 
viability, enhances adaptation and limits associated complications e.g. hepatic cholestasis. Regimes to 
achieve this include specialised feeds  and diets that transit the intestine most effectively and contain minimal 
residue. Continuous rather than bolus feeds via a gastrostomy or jejunostomy may be required 78,79,80. 
Drug use is largely limited to control of inflammation and immuno-modulation, and of bacterial 
overgrowth, with variable success reported with prokinetics 80,81. The best studied and apparently most 
effective motility agents such as cisapride and tegaserod are no longer available given safety concerns. 
Newer agents are being developed but not routinely available at present. Many current regimes to enhance 
intestinal motility are anecdotal or based case reports and include the use of, for example, the somatostatin 
analogue octreotide in combination with erythromycin 81. Sepsis by bacterial translocation or infection of 
central venous lines is a major consideration and antibiotic use is a valuable part of treatment.  
Surgery remains the most common intervention in patients with pseudo-obstruction with roles in 
diagnosis, feeding, symptom relief, bowel decompression, bypassing of diseased segments etc 82. In our 
practise the majority of children with CIPO will have formation of an ostomy early in the course of the 
disease. Maintaining bowel decompression (nasogastric tubes, venting gastrostomies or jejunostomies, 
surgical stomas) is valuable not only for symptomatic relief but also helps limit further deterioration in 
effective motility secondary to chronic distension. It often reduces pseudo-obstructive episodes and enhaces 
the tolerance of enteral feeding 80,81,83. Electrical pacing of the gastrointestinal wall using implantable 
pacemakers provides a potential therapy but remains experimental at present.  
Small bowel transplantation remains the only definitive cure with a number of centres reporting 
improved outcomes and survival 83,83. 
 
Prognosis 
Intestinal pseudo-obstruction remains a serious life-threatening disease with devastating effects for patients 
and their families, including significantly impaired quality of life 84.  The mortality is not clear but is thought 
to be in the order of 20-30% long-term 66,67. Increasing expertise in both the surgical and medical 
management has contributed to an improved prognosis especially to prevent complication such as sepsis and 
PN related liver disease. Outcomes from intestinal transplantation appear to be showing some improvement 
83,84. 
 
Summary and future perspectives 
CIPO presents a relatively rare but challenging group of conditions. Despite prolonged experience diagnosis 
remains difficult and management largely supportive. Initiatives to improve diagnosis and classification of 
disorders should help the identification and development of appropriate treatments. Recent advances raise 
possibilities for the use of novel pharmacologic agents and perhaps others such as cellular therapies to 
restore function. 
Gastrointestinal and nutritional problems in neurologically impaired children 
 
Introduction 
The current increasing survival of children with severe central nervous system damage has created a major 
challenge for medical care.  Although the primary problems for individuals with neuro-developmental 
disabilities are physical and mental incapacities, several clinical papers have reported that brain injuries may 
often result in significant gastrointestinal (GI) dysfunction 85,86,87,88. The enteric nervous system includes 
more nerve cells than the spinal cord and thus it is not surprising that any insult to the central nervous system 
may affect the complex integrated capacities underlying feeding and nutrition 89. Gastrointestinal and 
nutritional problems in neurologically impaired children have been recently recognized as an integral part of 
their disease, often leading to growth failure and worsened quality of life for both children and caregivers.  
The increased awareness of such conditions, together with a better understanding of their etiology and 
interplay, is essential to achieve an optimal global management of this group of children.  
 
Feeding and nutritional aspects 
Historically, severe malnutrition has been accepted as an unavoidable and irremediable consequence of 
neurological impairment.  Poor nutritional status was often marked by linear growth failure, decreased lean 
body mass, and diminished fat stores 90,91. Over the past two to three decades, the development of 
multidisciplinary feeding programs providing comprehensive evaluation and management of feeding 
disorders in children with developmental disabilities have been proven to improve nutritional status and 
impact upon quality of life and a reduction in hospitalization rates 92.  Studies on small numbers of children 
with developmental disabilities have demonstrated that adequate nutritional support, provided by less 
invasive enteral access methods and better tolerated enteral formulae, may improve weight, muscle mass, 
subcutaneous energy stores, peripheral circulation, the healing of decubitus ulcers and general well-being, 
whilst at the same time decreasing irritability and spasticity 93,94. 
The true prevalence of undernutrition in neurologically impaired children is unknown.  It has been 
estimated that approximately one-third are undernourished and many exhibit the consequences of 
malnutrition 7. Yet, the prevalence and severity of malnutrition increases in parallel with the duration and 
severity of neurological impairment 95,96,97.  The predominant nutritional deficit is in energy intake, given that 
only 20% of these children are regularly ingesting 100% of their estimated average requirement.  Moreover, 
half of the children with severe disabilities consumed less than 81% of the reference nutrient intake for 
copper, iron, magnesium, and zinc, influenced largely by their large consumption of milk 98. 
Nutritional support is essential for the care of neurologically impaired children. An individualized 
management plan accounting for the child’s nutritional status, feeding ability, and medical condition should 
be determined.  Energy requirements must be individualized considering muscle tone, mobility, activity 
level, altered metabolism and growth.  In order to increase energy intake, the easiest and least invasive 
approach is to improve oral intake.  Food caloric density may be increased by adding modular nutrients, 
modifying recipes or using high-calorie formulae.  Children who cannot chew effectively may be able to 
receive the same foods blended into a puree of acceptable consistency.  Those who can tolerate solids but not 
liquids can have commercial thickeners added to their fluids.  Oral feeding skills may be improved with 
rehabilitation therapy, even if the results are often disappointing 99,100,101.  Adequate positioning of the child 
during meals and appropriate food temperature are also important.  However, oral intake can be maintained 
as long as the child is growing well, there is no risk of aspiration, and the feeding time remains within 
acceptable limits. When oral intake is insufficient, unsafe, or too time-consuming enteral nutrition should be 
initiated. 
The type of enteral access will depend on the anticipated duration of enteral nutrition support as well 
as the clinical status of the child.  Nasogastric tubes are minimally invasive but are easily dislodged and may 
be associated with local complications such as otitis, sinusitis, congestion, and skin irritation.  Therefore, 
nasogastric feeds should only be used for short-term nutritional support (usually less than three months).  
When long-term enteral nutrition support is required, a gastrostomy should be considered.  Although more 
invasive, gastrostomies are more convenient and esthetically acceptable.  Gastrostomy placement has been 
shown to reduce feeding time, food-related choking episodes, frequency of chest infections, family stress, 
and to improve weight and nutritional status significantly in children with severe neurologic impairment 
95,102. Percutaneous gastrostomy (PEG), however, is not without complications or concerns.  Minor catheter 
infections, perforation and an overall reduced length of survival have being described in both adult and 
pediatric populations 103,103,104,105,106,107. 
The anatomy and function of the stomach should be carefully evaluated before the placement of the 
feeding tube.  The coexistence of gastro-oesophageal reflux may require a simultaneous fundoplication, and 
delayed gastric emptying may necessitate consideration of pyloroplasty or duodenal placement of the distal 
portion of the tube.  Physiologically designed formulas of increased caloric and protein density can be used 
for gastric and nasogastric infusion, as palatability is no longer an issue.  The choice between bolus and drip 
may depend on oesophago-gastric function, the volume to be delivered, or the home care needs of the child 
and his or her caregivers.  Often patients may benefit from a combination of daytime bolus and nocturnal 
continuous feeds, with the latter providing 30-50% of the child’s nutrient needs thus allowing more freedom 
for daily activities.  When safety of oral feeding is not an issue, these enteral techniques can merely 
supplement the child’s own nutrition, with caregivers continuing to feed the child actively.  This dual feeding 
method often provides great satisfaction to parents and caregivers given  the mealtime interaction is 
improved when there is no longer need for force-feeding of medication or nourishment.    
 
Gastrointestinal problems 
Chronic gastrointestinal disorders are very common in neurologically impaired children, with a reported 
prevalence of up to 92% 108. Dysphagia, rumination, gastro-oesophageal reflux (GOR), delayed gastric 
emptying, abdominal pain and constipation have all been described in this group of children, potentially 
contributing to feeding difficulties and carrying challenging long-term management issues.        
 
Dysphagia 
     Oro-motor dysfunction is a frequent concomitant issue and often one of the first signs of neuromuscular 
impairment.  Related swallowing problems have been shown to affect up to 90% of neurologically impaired 
children, and is a major contributor to malnutrition 86. This is not surprising since the development of oral-
motor skills mirrors general neurological maturation and requires coordination of the movement of several 
striated muscles in the mouth, pharynx and oesophagus, which are under the control of six cranial nerves, the 
brain stem and the cerebral cortex.  In addition, anatomic abnormalities such as cleft palate, laryngeal clefts, 
and tracheoesophageal fistula may accompany neurologic deficits as part of congenital or genetic syndromes.  
Dysphagia may manifest as distress during meals (including coughing, choking, and refusal of feeding), 
chronic or episodic aspiration-related respiratory disorders, and failure to thrive.  Barium swallow, cine-
swallow, radionuclide esophageal clearance scan, and oesophageal manometry may all be of some help in 
the clinical assessment.  Successful management of dysphagia is central to the child’s well-being and ability 
to achieve his or her potential. Neurologically impaired children often show greater problems with liquid 
foods, thus requiring the use of thickener products.  Oral motor exercise approaches using sensory modalities 
may help improving muscle strength and oral coordination.  Nevertheless, in most cases, the presence of 
unsafe swallows and/or prolonged distressing mealtimes finally leads to the use of enteral rather than oral 
nutrition. 
 
Gastro-oesophageal reflux. 
     Several reports have demonstrated a high incidence of GOR in children with neurological impairment.  
Increased intra-abdominal pressure secondary to spasticity and scoliosis, prolonged supine position,, and co-
existing hiatal hernia have been attributed as contributing factors to the increased frequency of GOR.  
Central nervous system dysfunction, however, is likely to be the primary cause, with GOR being part of the 
generalized dysmotility of the foregut or indeed the entire intestine.  Decreased resting pressure and 
increased frequency of transient relaxations of the lower oesophageal sphincter, together with oesophageal 
motility abnormalities, are probably a consequence of neuromuscular incoordination.   
     Currently the most accurate way of diagnosing GOR is 24-hour oesophageal pH impedance recording, 
which allows not only the quantification of reflux episodes but also helps in establishing the temporal 
relationship between GOR and the symptom complex in question.  The diagnostic work-up should then 
include upper GI endoscopy with multiple oesophageal biopsies and upper GI barium study, in order to 
evaluate the mucosa and to look for the possible presence of strictures, diverticuli, or hiatal herniae. 
Radionuclide studies such as gastric scintigraphy should also be performed, given the higher incidence of 
delayed gastric emptying which may contribute to GOR 109,110. An oesophageal manometry evaluating 
visceral motility may be helpful to detect the underlying pathophysiological mechanisms, especially when 
surgery is being considered.   
     Although children with neurologic impairment are more likely to have intractable reflux and eventually 
require some surgical procedures, medical therapy should be tried first.  When surgery is required, the Nissen 
fundoplication is currently the most widely used technique to strengthen the anti-reflux barrier and relieve 
symptoms. 
 
Constipation 
     Infrequent stool passage and hard bowel movements are very common in neurologically impaired 
children.  Total and sequential colonic transit times have been reported being prolonged and delayed mainly 
at the level of the left colon and rectum in this group of children, implying a probable defect in gut 
innervation 88.  The problem is usually exacerbated by prolonged immobility, inadequate fiber intake, and 
concurrent medications.  Unfortunately, recognition and effective management of constipation are often 
postponed because other disabilities overshadow those related to defecation.  The therapeutic approach needs 
to be tailored to the individual patient.  Oral or rectal disimpaction should be followed by promotion of 
regular bowel habit, through dietary modification, positioning, and use of laxative medications.  A 
significant number of children with neurological impairment needs to be on chronic doses of laxatives. This 
medical management is usually effective in enabling regular defecation, but where it fails, consideration 
should be given to a surgically placed appendicostomy. 
 
      
 
Cyclical Vomiting Syndrome 
 
Introduction 
Cyclic vomiting syndrome (CVS) is a disorder characterized by recurrent, stereotypical episodes of 
intense nausea and vomiting lasting few hours to days interspersed with symptom-free periods of varying 
length 111. In the majority of cases the underlying mechanisms remain unknown and patients are labeled as 
having idiopathic CVS. In children, the incidence of new cases has been reported to be 3.15/100,000 children 
per year, suggesting that CVS is more common than previously thought 112. Although CVS may occur in all 
age groups the average age at initial diagnosis is 5 years with often a delay in diagnosis of several years. In 
children with CVS, there is a recognized association with a personal history of headache or migraine (in up 
to 45%) and family history of migraine. CVS has a substantially negative impact on children’s quality of life, 
given that hospital admissions during the acute phase are rather common and that the condition significantly 
affects children’ activities of daily living and academic time 113. 
 
Pathophysiology 
The pathogenesis of CVS remains poorly understood and different mechanisms have been suggested 
including mitochondrial DNA (mtDNA) mutations responsible for deficits in cellular energy production, 
heightened hypothalamic-pituitary-adrenal (HPA) axis activation and autonomic nervous system (ANS) 
dysfunction 114,115,116. A unifying theory has recently been hypothesized suggesting that psychological and 
physical stress conditions initiate the cascade of HPA axis activation by releasing corticotrophin-releasing 
factor (CRF), which in turn inhibits the foregut motility by activating the inhibitory motor neurons in the 
dorsal motor nucleus of the vagus, and increases the adrenergic tone by activating the locus ceruleus in the 
lateral floor of the fourth ventricle. In concert, during stress conditions when needs are increased the 
impaired cellular energy production due to mtDNA mutations is unable to meet the heightened demand and 
predisposes individuals to the onset of vomiting cycle, and perpetuates the dysfunction of the autonomic 
neurons because of their high energy requirement. 
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Clinical presentation 
CVS has a typical on-off temporal pattern and is usually characterized by 4 different phases: 1. The 
interepisodic or well phase, which occurs between the vomiting episodes when the child is relatively 
symptom-free, and lasts weeks to months. 2. The prodromal phase, which is usually characterised by intense 
nausea, anorexia, pallor, lethargy and headache, and lasts minutes to hours. Usually, during this phase the 
child is still able to take and retain oral medication. 3. The emetic phase, during which the most common 
symptoms are intense nausea, vomiting, retching, listlessness, pallor, hypothermia or low grade fever, 
prostration, abdominal pain, diarrhoea, photophobia, phonophobia and hypertension in the Sato variant. The 
episodes may last from hours to days (up to 10 days), with a median duration of 24-27 hours. The frequency 
of the emetic phases ranges from 1 to 70 per year with an average of 12 episodes a year, and the number of 
emeses during each attack is at least 4 times/hour for at least 1 hour. It usually occurs early morning (2-4 
a.m.) or upon awakening (6-8 a.m.), and each episode tends to be stereotypical for each patient regarding the 
time of onset, the duration, intensity and symptomatology. Many patients show unusual specific behaviour 
features during the attacks aimed at lessening the intense nausea, such as being irritable, verbally abusive, 
and demanding, taking long hot showers or baths, drinking compulsively, and remaining in the foetal 
position in a dark and quite room. Finally, various complications may occur as consequence of intense and 
repetitive episodes of vomiting including dehydration and electrolytes imbalance, peptic esophagitis, gastritis 
and hematemesis due to Mallory-Weiss tears, weight loss and dental caries. Specific triggering factors are 
identified in almost two third of patients including psychological stressors (holiday, birthday, vacation, 
parental or interpersonal conflict), physical stressors (lack of sleep, excess physical exhaustion, menses), 
infections (upper respiratory infections, sinusitis) and dietary factors (glutamate, chocolate, cheese, allergy). 
4. The recovery phase, which begin when vomiting and nausea terminate and end when the child return to 
the normal activity. 
 
Diagnosis 
The diagnosis of CVS is primarily based on history and clinical presentation fulfilling the diagnostic 
criteria developed by North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, in 
the absence of other possible causes with similar presentation (Table 1) 117. There are no specific tests to 
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diagnose CVS, and currently the basic assessment includes FBC, amylase, lipase, liver function test, basic 
metabolic profile (glucose, BUN and electrolytes), and upper gastrointestinal contrast study to rule out 
anatomical abnormalities. In the presence of warning signals, such as bilious vomiting, severe abdominal 
pain, abdominal tenderness, episodes triggered by either fasting or high-protein meals, and abnormal 
neurological findings, further specific investigations should be promptly considered and tailored to the 
individual patient presentation. For instance, if there is a suspicion of metabolic and endocrine disorders 
additional laboratory tests, such as lactate, pyruvate, organic acid and amino acid analysis, plasma carnitine 
and acylcarnitine, plasma cortisol levels, and urinary prophyrins should be performed. Abdominal 
ultrasound, abdominal CT scan and upper gastrointestinal endoscopy should be considered in the presence of 
gastrointestinal alarm symptoms and signs. Finally, brain magnetic resonance imaging should be performed 
if a patient has neurologic manifestations. The differential diagnosis of disorders mimicking CVS is 
extensive and partially summarised in Table 2.         
 
Management 
The treatment of CVS is aimed at avoiding the trigger factors, terminating the acute phase, and preventing or 
reducing the frequency and intensity of acute episodes. Supportive and abortive measures during the acute 
episode include a dark and quiet environment, intravenous fluid, rescue agents as Ondansetron, Lorazepam 
and Chlorpromazine, and in older children Sumatriptan as an abortive agent 118. Prophylactic therapies are 
usually provided for those children with high recurrence and severity of episodes, and include as first-line 
agents Cyproheptadine, Pizotifen, and Amitriptiline, and Propanolol as a second line approach (8). In the last 
few years, the use of mitochondrial supplements, such as Riboflavin, L-carnitin and CoQ10, have been 
gradually increased based upon evidence of their efficacy in migraine.  
 
Prognosis 
Although the above treatments are effective in more than two third of cases, the management remains 
unsatisfactory in a significant number of the children who are referred to tertiary and quaternary centers.  
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Table 1 
Diagnostic criteria for childrewn with cylical vomiting syndrome suggested by the North American 
Society for Pediatric Gastroenterology, Hepatology and Nutrition Consensus Statement (7) 
 
1. At least 5 attacks in any interval, or a minimum of 3 attacks during a 6 month period 
2. Episodic attacks of intense nausea and vomiting lasting 1 hr-10 days and occurring at least 1 wk apart 
3. Stereotypical pattern and symptoms in the individual patient 
4. Vomiting during attacks occurs at least 4 times/hr for at least 1 hr 
5. Return to baseline health between episodes 
6. Not attributable to another disorder 
All of the criteria must be met to meet this consensus definition of CVS. 
 Table 2 
Differential diagnosis of cyclical vomiting in children and adolescents 
Gastrointestinal disorders 
- Bowel obstruction (malrotation with volvulus, duplication cyst, and intermittent intestinal 
intussusception) 
- Inflammatory diseases (gastritis, duodenitis, peptic ulcer disease, IBD=  
- Pancreatic diseases (pancreatitis and pancreatic pseudocyst) 
- Hepatobiliary disease (hepatitis) 
Infections 
- Enteritis 
- Otitis media, chronic sinusitis, and hepatitis 
Neurologic disorders 
- Migraine 
- Epilepsy 
- Space occupying central nervous system lesions (hydrocephalus, posterior fossa tumors, subdural 
hematoma, and subdural effusion) 
- Familial dysautonomia 
Metabolic and endocrine disorders 
- Diabetes mellitus, Addison disease, and pheochromocytoma 
- Aminoaciduria, organic aciduria, fatty acid oxidation disorders, mitochondrial disorders, and urea 
cycle defects 
Medications and toxins 
- Antibiotics, NSAID, laxatives, hormones, etc. 
Urologic/gynaecological disorders 
- Pelvi-ureteric junction obstruction 
- Nephrolithiasis 
Miscellaneous disorders 
- Abdominal migraines 
- Asthma 
- Benign paroxysmal positional vertigo 
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